{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T10:33:30Z","timestamp":1788604410163,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pneumonia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pneumonia is the most serious form of acute respiratory infection and\n                      <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                      is a leading cause of pediatric bacterial pneumonia. Pneumococcal conjugate vaccines were introduced in the United States (US) in 2000 (7-valent [PCV7]) and 2010 (13-valent [PCV13]). This study estimated annual incidence rates (IRs) of all-cause pneumonia (ACP) among US children aged\u2009&lt;\u200918\u00a0years before and after the introduction of PCV7 and PCV13.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ACP episodes were identified in the IBM MarketScan Commercial and Medicaid Databases using diagnosis codes. Annual IRs were calculated overall and by inpatient and outpatient settings as the number of episodes per 100,000 person-years (PY) for all children aged\u2009&lt;\u200918\u00a0years and by age group (&lt;\u20092, 2\u20134, and 5\u201317\u00a0years). National estimates of annual pneumonia IRs were extrapolated using Census Bureau data. Interrupted time series (ITS) analyses were used to assess immediate and gradual changes in monthly pneumonia IRs, adjusting for seasonality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the commercially-insured population, ACP IRs declined between the pre-PCV7 period (1998\u20131999) and late PCV13 period (2014\u20132018) from 5,322 to 3,471 episodes per 100,000 PY for children aged\u2009&lt;\u20092\u00a0years, from 4,012 to 3,794 episodes per 100,000 PY in children aged 2\u20134\u00a0years but increased slightly from 1,383 to 1,475 episodes per 100,000 PY in children aged 5\u201317\u00a0years. The ITS analyses indicated significant decreases in monthly ACP IRs in the early PCV7 period (2001\u20132005) among younger children and in the early PCV13 period (2011\u20132013) among all children. Increases were observed in the late PCV7 period (2006\u20132009) among all age groups, but were only significant among older children. IRs of inpatient ACP decreased across all age groups, but outpatient pneumonia IRs remained stable during the study timeframe, even increasing slightly in children aged 5\u201317\u00a0years. More prominent declines were observed for Medicaid-insured children across all age groups; however, Medicaid IRs were higher than IRs of commercially-insured children during the entire study timeframe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ACP disease burden remains high in US children of all ages despite overall reductions in incidence rates during 1998\u20132018 following the introduction of PCV7 and PCV13.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41479-023-00109-5","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T20:03:14Z","timestamp":1680638594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Tianyan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Sarpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Done","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Lemus-Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salini","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"109_CR1","unstructured":"UNICEF. Pneumonia 2020 [Available from: https:\/\/data.unicef.org\/topic\/child-health\/pneumonia\/."},{"issue":"1","key":"109_CR2","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2214-109X(18)30408-X","volume":"7","author":"DA McAllister","year":"2019","unstructured":"McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: A systematic analysis. Lancet Glob Health. 2019;7(1):e47\u201357.","journal-title":"Lancet Glob Health"},{"issue":"9","key":"109_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJMoa1405870","volume":"372","author":"S Jain","year":"2015","unstructured":"Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among US children. N Engl J Med. 2015;372(9):835\u201345.","journal-title":"N Engl J Med"},{"key":"109_CR4","unstructured":"World Health Organization. Pneumonia https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/pneumonia2019 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/pneumonia."},{"issue":"3","key":"109_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijpam.2019.04.002","volume":"6","author":"S Sulley","year":"2019","unstructured":"Sulley S, Ndanga M. Pediatric pneumonia: An analysis of cost & outcome influencers in the United States. Int J Pediatr Adolesc Med. 2019;6(3):79\u201386.","journal-title":"Int J Pediatr Adolesc Med"},{"issue":"Suppl 2","key":"109_CR6","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2011-200598","volume":"66","author":"M Harris","year":"2011","unstructured":"Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: Update 2011. Thorax. 2011;66(Suppl 2):ii1-23.","journal-title":"Thorax."},{"issue":"10","key":"109_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1034\/j.1600-0463.2003.1111005.x","volume":"111","author":"T Heiskanen-Kosma","year":"2003","unstructured":"Heiskanen-Kosma T, Korppi M, Leinonen M. Serologically indicated pneumococcal pneumonia in children: a population-based study in primary care settings. APMIS. 2003;111(10):945\u201350.","journal-title":"APMIS"},{"issue":"1","key":"109_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/000992280504400101","volume":"44","author":"SI Pelton","year":"2005","unstructured":"Pelton SI, Hammerschlag MR. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clin Pediatr. 2005;44(1):1\u201317.","journal-title":"Clin Pediatr"},{"key":"109_CR9","doi-asserted-by":"crossref","unstructured":"Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106(2):362\u20136.","DOI":"10.1542\/peds.106.2.362"},{"key":"109_CR10","unstructured":"Centers for Disease Control and Prevention (CDC). Pneumococcal vaccine recommendations 2022 [Available from: https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/recommendations.html."},{"key":"109_CR11","unstructured":"Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among children aged 19\u201335 months - United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(33):921\u20136."},{"key":"109_CR12","unstructured":"Centers for Disease Control and Prevention (CDC). Pneumococcal disease: Surveillance and reporting 2020 [Available from: https:\/\/www.cdc.gov\/pneumococcal\/surveillance.html."},{"issue":"9","key":"109_CR13","first-page":"139","volume":"113","author":"H Ewald","year":"2016","unstructured":"Ewald H, Briel M, Vuichard D, Kreutle V, Zhydkov A, Gloy V. The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials. Dtsch Arztebl Int. 2016;113(9):139.","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"109_CR14","first-page":"CD004977","volume":"2009","author":"MG Lucero","year":"2009","unstructured":"Lucero MG, Dulalia VE, Nillos LT, Williams G, Parre\u00f1o RAN, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;2009(4):CD004977.","journal-title":"Cochrane Database Syst Rev."},{"issue":"7","key":"109_CR15","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1073\/pnas.1612833114","volume":"114","author":"CA Bruhn","year":"2017","unstructured":"Bruhn CA, Hetterich S, Schuck-Paim C, K\u00fcr\u00fcm E, Taylor RJ, Lustig R, et al. Estimating the population-level impact of vaccines using synthetic controls. Proc Natl Acad Sci. 2017;114(7):1524\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"17","key":"109_CR16","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1056\/NEJMc1310477","volume":"369","author":"MR Griffin","year":"2013","unstructured":"Griffin MR, Grijalva CG. Hospitalizations after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(17):1662.","journal-title":"N Engl J Med"},{"issue":"4","key":"109_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.vaccine.2015.12.003","volume":"34","author":"D Chang","year":"2016","unstructured":"Chang D, Bednarczyk RA, Becker ER, Hockenberry JM, Weiss PS, Orenstein WA, et al. Trends in US hospitalizations and inpatient deaths from pneumonia and influenza, 1996\u20132011. Vaccine. 2016;34(4):486\u201394.","journal-title":"Vaccine"},{"issue":"9568","key":"109_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0140-6736(07)60564-9","volume":"369","author":"CG Grijalva","year":"2007","unstructured":"Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568):1179\u201386.","journal-title":"Lancet"},{"issue":"2","key":"109_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1542\/peds.2009-3109","volume":"126","author":"GE Lee","year":"2010","unstructured":"Lee GE, Lorch SA, Sheffler-Collins S, Kronman MP, Shah SS. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126(2):204\u201313.","journal-title":"Pediatrics"},{"issue":"12","key":"109_CR20","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/archpedi.161.12.1162","volume":"161","author":"F Zhou","year":"2007","unstructured":"Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161(12):1162\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"109_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-017-2770-6","volume":"18","author":"S Tong","year":"2018","unstructured":"Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008\u20132014. BMC Health Serv Res. 2018;18(1):1\u20138.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"109_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.chest.2017.09.041","volume":"153","author":"BH Hayes","year":"2018","unstructured":"Hayes BH, Haberling DL, Kennedy JL, Varma JK, Fry AM, Vora NM. Burden of pneumonia-associated hospitalizations: United States, 2001\u20132014. Chest. 2018;153(2):427\u201337.","journal-title":"Chest"},{"issue":"5","key":"109_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(14)70032-3","volume":"2","author":"L Simonsen","year":"2014","unstructured":"Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(5):387\u201394.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"109_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1542\/peds.2006-0492","volume":"118","author":"CG Grijalva","year":"2006","unstructured":"Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. 2006;118(3):865\u201373.","journal-title":"Pediatrics"},{"issue":"3","key":"109_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1542\/peds.2010-2008","volume":"127","author":"MP Kronman","year":"2011","unstructured":"Kronman MP, Hersh AL, Feng R, Huang Y-S, Lee GE, Shah SS. Ambulatory visit rates and antibiotic prescribing for children with pneumonia, 1994\u20132007. Pediatrics. 2011;127(3):411\u20138.","journal-title":"Pediatrics"},{"issue":"45","key":"109_CR26","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1016\/j.vaccine.2018.02.113","volume":"36","author":"D Greenberg","year":"2018","unstructured":"Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36(45):6883\u201391.","journal-title":"Vaccine"},{"issue":"8","key":"109_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/INF.0000000000002765","volume":"39","author":"HL Platt","year":"2020","unstructured":"Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, et al. A phase ii trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020;39(8):763\u201370.","journal-title":"Pediatr Infect Dis J"},{"key":"109_CR28","unstructured":"Pfizer Inc. Pfizer announces positive preliminary results from a proof-of-concept phase 2 study (B7471003) of its 20-valent pneumococcal conjugate vaccine candidate being investigated for the prevention of invasive disease and otitis media in healthy infants 2019 [updated September 09, 2019. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_announces_positive_preliminary_results_from_a_proof_of_concept_phase_2_study_b7471003_of_its_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and."},{"key":"109_CR29","unstructured":"Pneumococcal Conjugate Vaccine (PCV) coverage among children 19\u201335 months by state, HHS region, and the United States, National Immunization Survey-Child (NIS-Child), 2002 through 2017. 2022 [cited July 10, 2022 ]. Available from: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/childvaxview\/interactive-reports\/index.html."},{"issue":"5","key":"109_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.15585\/mmwr.mm6705e2","volume":"67","author":"CL Robinson","year":"2018","unstructured":"Robinson CL, Romero JR, Kempe A, Pellegrini C, Szilagyi P. Advisory Committee on immunization practices recommended immunization schedule for adults aged 18 years or younger \u2014 United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(5):156\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"109_CR31","unstructured":"Centers for Disease Control and Prevention (CDC). Pneumococcal vaccination: Summary of who and when to vaccinate [Available from: https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/who-when-to-vaccinate.html"},{"issue":"158","key":"109_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209\u201312.","journal-title":"J Am Stat Assoc"},{"key":"109_CR33","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","volume":"6","author":"B Wahl","year":"2018","unstructured":"Wahl B, O\u2019Brien K, Greenbaum A, Liu L, Chu Y, Majumder A, et al. Global, regional, and national burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: updated estimates from 2000\u20132015. Lancet Glob Health. 2018;6:e744\u201357.","journal-title":"Lancet Glob Health"},{"issue":"7","key":"109_CR34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","volume":"16","author":"MP Fay","year":"1997","unstructured":"Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: A method based on the gamma distribution. Stat Med. 1997;16(7):791\u2013801.","journal-title":"Stat Med"},{"issue":"6","key":"109_CR35","doi-asserted-by":"publisher","first-page":"e20170953","DOI":"10.1542\/peds.2017-0953","volume":"140","author":"M Venkataramani","year":"2017","unstructured":"Venkataramani M, Pollack CE, Roberts ET. Spillover effects of adult Medicaid expansions on children\u2019s use of preventive services. Pediatrics. 2017;140(6):e20170953.","journal-title":"Pediatrics."},{"issue":"9","key":"109_CR36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1089\/jwh.2020.8776","volume":"30","author":"W Lyu","year":"2021","unstructured":"Lyu W, Wehby GL. Heterogeneous effects of Affordable Care Act Medicaid expansions among women with dependent children by state-level pre-expansion eligibility. J Women\u2019s Health. 2021;30(9):1278\u201387.","journal-title":"J Women's Health"},{"key":"109_CR37","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.3389\/fmicb.2018.02670","volume":"9","author":"B Beall","year":"2018","unstructured":"Beall B, Chochua S, Gertz RE Jr, Li Y, Li Z, McGee L, et al. A population-based descriptive atlas of invasive pneumococcal strains recovered within the US during 2015\u20132016. Front Microbiol. 2018;9:2670.","journal-title":"Front Microbiol"},{"issue":"49","key":"109_CR38","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.1016\/j.vaccine.2020.10.005","volume":"38","author":"Q Wang","year":"2020","unstructured":"Wang Q, Shi W, Li Y, Gao W, Yuan L, Dong F, et al. Serotype distribution of Streptococcus pneumoniae isolated from children hospitalized in Beijing children\u2019s hospital (2013\u20132019). Vaccine. 2020;38(49):7858\u201364.","journal-title":"Vaccine"},{"issue":"9","key":"109_CR39","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","volume":"21","author":"SB Black","year":"2002","unstructured":"Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. J Pediatr Infect Dis. 2002;21(9):810\u20135.","journal-title":"J Pediatr Infect Dis"},{"issue":"3","key":"109_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1586\/erv.10.6","volume":"9","author":"RR Reinert","year":"2010","unstructured":"Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines. 2010;9(3):229\u201336.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"109_CR41","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1128\/CMR.00024-15","volume":"28","author":"KA Geno","year":"2015","unstructured":"Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28(3):871\u201399.","journal-title":"Clin Microbiol Rev"},{"key":"109_CR42","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2147\/COPD.S83135","volume":"10","author":"DM Kern","year":"2015","unstructured":"Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, et al. Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population. Int J Chron Obstruct Pulmon Dis. 2015;10:1417\u201325.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"109_CR43","doi-asserted-by":"crossref","first-page":"233339282093980","DOI":"10.1177\/2333392820939801","volume":"7","author":"RB Smithee","year":"2020","unstructured":"Smithee RB, Markus TM, Soda E, Grijalva CG, Xing W, Shang N, et al. Pneumonia hospitalization coding changes associated with transition from the 9th to 10th revision of International Classification of Diseases. Health Serv Res Manag Epidemiol. 2020;7:2333392820939801.","journal-title":"Health Serv Res Manag Epidemiol"}],"container-title":["Pneumonia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-023-00109-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41479-023-00109-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-023-00109-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T20:06:12Z","timestamp":1680638772000},"score":1,"resource":{"primary":{"URL":"https:\/\/pneumonia.biomedcentral.com\/articles\/10.1186\/s41479-023-00109-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["109"],"URL":"https:\/\/doi.org\/10.1186\/s41479-023-00109-5","relation":{},"ISSN":["2200-6133"],"issn-type":[{"value":"2200-6133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved de-identified, aggregate data and was not subject to Institutional Review Board approval at Merck & Co., Inc., Rahway, NJ, USA or Analysis Group, Inc. Informed consent was not needed as all patients were anonymized and only aggregate data are reported here. A research review committee at Merck & Co., Inc., Rahway, NJ, USA approved the study protocol prior to the study initiation. All methods were performed in accordance with the relevant guidelines and regulations, including the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EMS, SM, and TW are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. TH was an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, at the time the study was conducted. YS, ND, QL, ELW, and JS are employees of Analysis Group Inc., a consulting firm that received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, to conduct this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}